InterPAD - DETAILS

Dapagliflozin, 461432-26-8, BMS-512148, Forxiga, BMS 512148, (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, Dagagflozin, UNII-1ULL0QJ8UC, (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol, 1ULL0QJ8UC, CHEBI:85078, LYN-045, (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol, CHEMBL429910, DTXSID20905104, Dapagliflozin [USAN:INN], QTERNMET COMPONENT DAPAGLIFOZIN, DAPAGLIFLOZIN COMPONENT QTERNMET, (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, QTERNMET XR COMPONENT DAPAGLIFLOZIN, Forxiga (TN), D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-, CHEMBL3125458, BMS512148, (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol, (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, Dapagliflozin [USAN], dapagliflozine, dapagliflozinum, Dapagliflozina, (1S)-1,5-anhydro-1-(4-chloro-3-(4-ethoxybenzyl)phenyl)-D-glucitol, (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol, (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; BMS 512148; Dapagliflozin; Farxiga, (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol, DAPAGLIFLOZIN?, S1548_Selleck, C-aryl glucoside, 6, DAPAGLIFLOZIN [MI], DAPAGLIFLOZIN [INN], Dapagliflozin (USAN/INN), 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol, DAPAGLIFLOZIN [VANDF], SCHEMBL157820, DAPAGLIFLOZIN [WHO-DD], GTPL4594, BR1019 component Dapagliflozin, BDBM20880, A10BK01, EX-A005, JVHXJTBJCFBINQ-ADAARDCZSA-N, BCPP000265, DTXCID101334207, DAPAGLIFLOZIN [ORANGE BOOK], AMY18541, BDBM50448923, MFCD13182359, s1548, AKOS005145763, BCP9000583, BL-0052, BMS5121458, CCG-229917, CS-0781, DB06292, EX-7214, NCGC00250402-09, AC-24699, BD164346, HY-10450, DAPAGLIFLOZIN COMPONENT OF QTERNMET XR, NS00099173, A25150, C22193, D08897, EN300-7407160, Q409898, J-500392, BRD-K58160573-001-01-3, BRD-K58160573-001-05-4, Z2235801883, (2S, 3R, 4R, 5S, 6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol, (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol, (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;BMS-512148, (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol, LE6

Name	Dapagliflozin
PubChem CID	9887712
Molecular Weight	408.9g/mol
Synonyms	Dapagliflozin, 461432-26-8, BMS-512148, Forxiga, BMS 512148, (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, Dagagflozin, UNII-1ULL0QJ8UC, (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol, 1ULL0QJ8UC, CHEBI:85078, LYN-045, (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol, CHEMBL429910, DTXSID20905104, Dapagliflozin [USAN:INN], QTERNMET COMPONENT DAPAGLIFOZIN, DAPAGLIFLOZIN COMPONENT QTERNMET, (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, QTERNMET XR COMPONENT DAPAGLIFLOZIN, Forxiga (TN), D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-, CHEMBL3125458, BMS512148, (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol, (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, Dapagliflozin [USAN], dapagliflozine, dapagliflozinum, Dapagliflozina, (1S)-1,5-anhydro-1-(4-chloro-3-(4-ethoxybenzyl)phenyl)-D-glucitol, (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol, (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; BMS 512148; Dapagliflozin; Farxiga, (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol, DAPAGLIFLOZIN?, S1548_Selleck, C-aryl glucoside, 6, DAPAGLIFLOZIN [MI], DAPAGLIFLOZIN [INN], Dapagliflozin (USAN/INN), 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol, DAPAGLIFLOZIN [VANDF], SCHEMBL157820, DAPAGLIFLOZIN [WHO-DD], GTPL4594, BR1019 component Dapagliflozin, BDBM20880, A10BK01, EX-A005, JVHXJTBJCFBINQ-ADAARDCZSA-N, BCPP000265, DTXCID101334207, DAPAGLIFLOZIN [ORANGE BOOK], AMY18541, BDBM50448923, MFCD13182359, s1548, AKOS005145763, BCP9000583, BL-0052, BMS5121458, CCG-229917, CS-0781, DB06292, EX-7214, NCGC00250402-09, AC-24699, BD164346, HY-10450, DAPAGLIFLOZIN COMPONENT OF QTERNMET XR, NS00099173, A25150, C22193, D08897, EN300-7407160, Q409898, J-500392, BRD-K58160573-001-01-3, BRD-K58160573-001-05-4, Z2235801883, (2S, 3R, 4R, 5S, 6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol, (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol, (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;BMS-512148, (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol, LE6
Drug Type	Small molecule
Formula	C₂₁H₂₅ClO₆
SMILES	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl
InChI	1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
InChIKey	JVHXJTBJCFBINQ-ADAARDCZSA-N
CAS Number	461432-26-8
ChEMBL ID	CHEMBL429910
ChEBI ID	CHEBI:85078
TTD ID	D01TNW
Drug Bank ID	DB06292
KEGG ID	C22193
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Niacinamide, Dapagliflozin
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.